Gilead Sciences

The cover story in this week's Barron's offers suggestions for a more sophisticated strategy for investing in emerging markets. Gone are the days when all it took to make money was to buy the index or a fund that did not stray far from it. Among the BRIC countries, the large emerging economies...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of February. The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of February. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Illumina (NASDAQ: ILMN) and Vertex Pharmaceuticals (NASDAQ: VRTX) grew somewhat between the January 31...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the latter two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Vertex Pharmaceuticals (NASDAQ: VRTX) and VIVUS...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of December. The number of shares sold short in Amgen (NASDAQ: AMGN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN) and Illumina (NASDAQ: ILMN) grew somewhat between the...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of November. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Illumina (NASDAQ: ILMN) and Regeneron Pharmaceuticals (NASDAQ: REGN) grew somewhat between the November 15 and...

Three of Fortune's top 10 stock picks for 2013 are health care related companies. But they are not in big names in the sector, such as Johnson & Johnson (NYSE: JNJ) or Pfizer (NYSE: PFE). They were Align Technology (NASDAQ: ALGN), Fresenius Medical Care (NYSE: FMS) and Gilead Sciences (NASDAQ:...

Here is a quick look at some of the top-performing health care sector stocks in the past month. These companies all have a market cap of more than $500 million, and their share prices are more than 20 percent higher than 30 days ago. BioMarin Pharmaceutical (NASDAQ: BMRN) in early November...

Here is a quick look at some of the top-performing Nasdaq stocks in the past month. These companies all have a market cap of more than $500 million and their share prices are more than 40 percent higher than 30 days ago. Green Mountain Coffee Roasters (NASDAQ: GMCR) shares jumped more than 32...

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of October. Shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between...

The short interest in biotech and emerging pharmaceutical companies was mixed in the first two weeks of October. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ...

After largely rising in the previous period, short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of September. Shares sold short in Amgen (NASDAQ: AMGN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN), Onyx...

Here is a quick look at three top-performing biotech stocks, each with a consensus recommendation (among analysts) of Strong Buy. They are Ariad Pharmaceuticals (NASDAQ: ARIA), Merrimack Pharmaceuticals (NASDAQ: MACK) and Synageva BioPharma (NASDAQ: GEVA). Ariad Pharmaceuticals Shares of this...

The short interest data is out from the September 14 settlement date. By and large, short sellers have resumed their gambles on biotech firms compared to the August 31 settlement date. Short interest had waned for the most part in the two weeks before the end of August. Two notable exceptions to...